Enzalutamide and Androgen Receptor Inhibition in CRPC

How does enzalutamide inhibit androgen receptor signaling in CRPC?

Enzalutamide inhibits androgen receptor signaling in CRPC by blocking androgen binding to the receptor, preventing nuclear translocation of the AR complex, impairing AR-DNA binding, and inhibiting coactivator recruitment, thereby disrupting AR-mediated transcription at multiple steps in the signaling pathway.

Abstract

Enzalutamide inhibits androgen receptor (AR) signaling in castration-resistant prostate cancer (CRPC) through multiple concurrent mechanisms: blocking androgen binding to the AR, preventing nuclear translocation of the AR complex, impairing AR-DNA binding, and inhibiting coactivator recruitment. Clinical evidence demonstrates this inhibition causes AR relocalization from nucleus to cytoplasm in responding patients, resulting in apoptosis, suppressed proliferation, PSA decline (45% of patients achieving ≥50% reduction), and improved overall survival (18.4 vs. 13.6 months). However, CRPC frequently develops resistance through mechanisms that bypass or overcome this inhibition, including expression of AR splice variants lacking the ligand-binding domain (AR-V7), acetylation of AR at lysine 609 that allows nuclear translocation despite drug presence, rewiring to noncanonical AR signaling through CXXC5 and TET2 pathways, and activation of non-AR compensatory pathways such as CXCR7-mediated MAPK signaling. Tumors with high baseline nuclear AR expression (>75%) and CYP17 expression (>10%) show better response to enzalutamide, while presence of AR-V7 predicts primary resistance. The evidence indicates enzalutamide effectively blocks canonical AR signaling in dependent tumors, but multiple molecular adaptations allow CRPC to maintain proliferative signaling through AR-variant, post-translationally modified, noncanonical, or non-AR pathways.

Methods

We analyzed 10 sources from an initial pool of 200, using 5 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question. More on methods

• Records from Elicit search

  • n = 200

• Papers screened using: Patient Population, Primary Intervention, Mechanistic Data, Study Design, Cancer Type Appropriateness

  • n = 200 Papers screened out
  • n = 190 Papers included for extraction
  • n = 10

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

We ran this query: “How does enzalutamide inhibit androgen receptor signaling in CRPC?”

The search returned 200 total results from Elicit. We retrieved 200 papers most relevant to the query for screening.

Screening

We screened in sources based on their abstracts that met these criteria:

• Patient Population: Does this study involve patients diagnosed with castration-resistant prostate cancer (CRPC)?
• Primary Intervention: Does this study investigate enzalutamide as a primary intervention?
• Mechanistic Data: Does this study measure or analyze androgen receptor signaling pathways, biomarkers, or related molecular mechanisms?
• Study Design: Is this study a randomized controlled trial, cohort study, case-control study, case series with adequate sample size, or experimental study?
• Cancer Type Appropriateness: Does this study include castration-resistant prostate cancer patients?

Data extraction

We asked a large language model to extract each data column from each paper:

• Enzalutamide AR Inhibition Mechanisms:

  • Effects on AR nuclear translocation
  • Effects on AR-DNA binding
  • Effects on AR transcriptional activity
  • Effects on AR protein interactions (coactivators, cofactors)
  • Effects on AR post-translational modifications
  • Effects on AR variant activities
  • Effects on downstream AR signaling pathways
  • Molecular targets and binding sites
  • Time course of inhibition effects

• CRPC Model System:

  • Type of model (cell lines, xenografts, patient samples, organoids)
  • Specific cell line names or patient characteristics
  • Whether models were enzalutamide-sensitive or resistant
  • Key characteristics of the CRPC model (AR status, mutations, treatment history)
  • In vivo vs in vitro experimental conditions

• AR Signaling Measurement Methods:

  • Techniques for measuring AR transcriptional activity
  • Methods for assessing AR nuclear localization
  • Approaches for measuring AR-DNA binding (ChIP-seq, etc.)
  • AR target gene expression analysis methods
  • Protein interaction assays
  • Functional readouts of AR activity
  • Quantitative measures and statistical approaches

• Resistance Mechanisms:

  • AR structural changes or mutations that confer resistance
  • Alternative AR signaling pathways that bypass enzalutamide inhibition
  • Post-translational modifications that restore AR function
  • AR variant expression that escapes inhibition
  • Non-AR pathways that compensate for AR inhibition
  • Timeline of resistance development

• Functional Consequences:

  • Effects on cell proliferation and survival
  • Changes in gene expression profiles
  • Effects on tumor growth in vivo
  • Biomarker changes (PSA, etc.)
  • Cellular phenotype changes
  • Duration of effects
  • Dose-response relationships for functional outcomes

• AR Signaling Context:

  • Baseline AR expression levels and activity
  • Presence of AR variants or mutations
  • Androgen levels in the experimental system
  • Other concurrent treatments or conditions
  • Tumor microenvironment factors
  • Patient characteristics that affect AR signaling
  • Temporal factors (treatment duration, progression stage)

Results

Characteristics of Included Studies

The review included 10 sources examining enzalutamide’s mechanisms of action in CRPC. Studies varied in design, focusing on clinical trial data or molecular mechanisms in preclinical models.

The studies employed diverse experimental approaches. Clinical studies examined patient samples using bone marrow biopsies, assessing outcomes including PSA response, overall survival, and biomarker expression. Preclinical studies utilized both enzalutamide-sensitive and resistant cell line models, generating resistance through chronic drug exposure. Measurement techniques included ChIP-seq for AR-DNA binding, RNA-seq for gene expression profiling, and functional assays for cell proliferation and tumor growth.

Mechanisms of AR Signaling Inhibition

Enzalutamide employs multiple complementary mechanisms to disrupt androgen receptor signaling. The drug blocks androgen binding to the AR, preventing the ligand-receptor interaction required for AR activation. Following this, enzalutamide inhibits nuclear translocation of the AR complex, sequestering the receptor in the cytoplasm. Once in the nucleus, AR function is further impaired through inhibition of AR-DNA binding, preventing the receptor from occupying androgen response elements on target gene promoters. Additionally, enzalutamide blocks coactivator recruitment to the AR complex, disrupting transcriptional machinery required for gene expression. Importantly, unlike older antiandrogens, enzalutamide provides more complete antagonism.

Effects of Successful AR Inhibition

When enzalutamide successfully inhibits AR signaling, multiple downstream consequences occur, including delayed tumor growth in vivo, reduced PSA levels, and beneficial clinical outcomes. Clinical outcomes from the AFFIRM trial demonstrated substantial benefits when AR signaling was effectively blocked, improving overall survival compared to placebo.

Mechanisms of Resistance to AR Inhibition

Despite enzalutamide’s inhibition of AR signaling, CRPC frequently develops resistance through several mechanisms, including:

AR Variant Expression

Expression of AR splice variants, particularly AR-V7, represents a major resistance mechanism that results in treatment failure.

Post-Translational Modifications

Acetylation of AR at lysine 609 facilitates AR translocation to the nucleus despite drug presence, creating feedback loops that sustain AR expression.

Noncanonical AR Signaling

Enzalutamide-resistant cells maintain AR dependence through noncanonical mechanisms, showcasing altered AR binding patterns.

Non-AR Compensatory Pathways

Non-AR pathways such as CXCR7 and glucocorticoid receptor upregulation provide alternate routes for proliferative signaling, contributing to resistance.

Predictive Biomarkers and Contextual Factors

Baseline characteristics, including AR expression levels, presence of AR-V7, and androgen levels, predict response to enzalutamide, demonstrating the heterogeneity in treatment efficacy across CRPC tumors.

Synthesis

The evidence reveals that enzalutamide functions through a multi-step mechanism of AR signaling inhibition, with clinical responses exhibiting substantial variability driven by molecular contexts.